Proliferative diabetic retinopathy (PDR) is the leading cause for blindness in working-age adults. The current gold standard treatment for PDR is panretinal photocoagulation (PRP). In current clinical practice, both single-session and multiple-session PRP approaches are widely accepted and utilized. The purpose of this study is to compare the safety and effectiveness of single-session and multiple-session PRP.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Central subfield retinal thickness (CRT)
Timeframe: Baseline and 1, 3 and 6 months after treatment
Vessel Perfusion Density (VPD)
Timeframe: Baseline and 1, 3 and 6 months after treatment
Vessel Length Density (VLD)
Timeframe: Baseline and 1, 3 and 6 months after treatment
Foveal Avascular Zone (FAZ)
Timeframe: Baseline and 1, 3 and 6 months after treatment
Lesion size
Timeframe: Baseline and 1, 3 and 6 months after treatment
Macular volume
Timeframe: Baseline and 1, 3 and 6 months after treatment
Venular saturation
Timeframe: Baseline and 1, 3 and 6 months after treatment
Arteriolar saturation
Timeframe: Baseline and 1, 3 and 6 months after treatment
Imadeddin Abu Ishkheidem, M.D.
Retinal diameter
Timeframe: Baseline and 1, 3 and 6 months after treatment
Venular diameter
Timeframe: Baseline and 1, 3 and 6 months after treatment
Retinal function
Timeframe: Baseline and 1, 3 and 6 months after treatment
Diabetic macular edema (DME)
Timeframe: Baseline and 1, 3 and 6 months after treatment
Subjective experience of pain after treatment
Timeframe: Baseline and 1, 3 and 6 months after treatment
Subjective overall experience of the treatment
Timeframe: Baseline and 1, 3 and 6 months after treatment
Cost-effectiveness
Timeframe: Baseline and 1, 3 and 6 months after treatment